Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews · Eyes and Vision

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Rituximab vs placebo

Motility · thyroid‐associated ophthalmopathy

1 finding from 1 review

Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 25 participants
Very low

Rituximab vs intravenous methylprednisolone

Motility improvement (increase) by 1 class or more · thyroid‐associated ophthalmopathy

It is very uncertain whether summary of findings table ‐ Rituximab changes motility improvement (increase) by 1 class or more compared with intravenous methylprednisolone (very low certainty).

1 finding from 1 review

Rituximab for thyroid‐associated ophthalmopathy 2022 · Cochrane Headline outcomes only
RR 1.07 [0.25, 4.49]
1 study · 31 participants
Very low